Is Spravato® FDA-approved for PTSD?

No. It is FDA-approved for TRD and for depressive symptoms in MDD with acute suicidal ideation or behavior. PTSD-specific use is off-label and considered case by case after standard therapies are optimized.

How fast might symptoms change?

Mood can improve in days; PTSD clusters (re-experiencing, hyperarousal, sleep) often improve over 4 to 8 weeks when sessions are paired with EMDR/CBT.

Do I still need EMDR/CBT?

Yes. We strongly recommend coordinating therapy to reinforce new learning during periods of increased neuroplasticity.

What are common side effects?

Transient dissociation, dizziness, nausea, and temporary blood-pressure increases. You will be monitored throughout the visit and should not drive until the next day.

Can esketamine be combined with TMS?

Yes. For TRD plus PTSD, combined or sequenced approaches (esketamine, TMS and EMDR/CBT) may optimize speed and durability. We individualize the plan.

Spravato® for PTSD | Florida TMS Clinic

Off-label notice

Spravato® (esketamine) is FDA-approved for TRD and for depressive symptoms in MDD with acute suicidal ideation or behavior, not specifically for PTSD. We consider it when PTSD coexists with TRD and standard therapies are optimized.

Why consider esketamine for PTSD?

Many PTSD patients also live with TRD. Esketamine (an NMDA receptor modulator) can rapidly lift mood and improve neuroplasticity, supporting fear extinction, emotion regulation, and reconsolidation of traumatic memories. Pairing dosing visits with EMDR or CBT may help consolidate these gains.

Fast antidepressant effect: improvements often within 24 to 72 hours.
PTSD symptom gains: open-label cohorts show reductions in re-experiencing, hyperarousal, and sleep problems over weeks.
Therapy synergy: aligning EMDR/CBT with esketamine's plasticity window can support healing.

What the evidence shows (current, evolving)

VA San Diego case series (n=35), intranasal esketamine in veterans with TRD and PTSD: PCL-5 fell about 15 points over induction, and about 46% reached at least a 30% PTSD improvement. PHQ-9 fell about 5 points; some PTSD gains emerged even when depression response was modest.
Frontiers in Psychiatry real-world series (n=11), 6-month follow-up with maintenance: improvements in MADRS and PHQ-9, functioning, and suicidality across months, supporting a taper to every 2 to 4 weeks for durability.
Medication-enhanced psychotherapy (n=6), esketamine plus EMDR, supportive therapy or hypnosis: MADRS fell about 12.6 on average and PCL-5 fell 10 to 46 points across patients. Largest gains were in re-experiencing, negative mood and cognition, and hyperarousal; avoidance may lag and can be targeted in therapy.
Heliyon, oral esketamine (n=5), 1 to 2 times weekly plus psychotherapy: 4 of 5 improved in depression and resilience; 1 worsened after a real-life trigger, which emphasizes trauma-informed monitoring.

Evidence is preliminary (open-label and retrospective). We individualize decisions and track outcomes with measurement-based care.

How treatment works at Florida TMS Clinic

Flashbacks: some patients experience brief trauma recall during early sessions. With grounding and orientation, these episodes often diminish and can be therapeutically useful rather than adverse.

Eligibility and planning: confirm PTSD and TRD history, prior trials, suicidality, and medical suitability.
Program: induction typically 2 visits per week for about 4 weeks, then weekly, then every 2 to 4 weeks per response (56 to 84 mg intranasal under REMS).
Visit length: about 2 hours including administration, recovery, and monitoring (vitals, comfort).
Aftercare: no driving until the next day; arrange a safe ride.
Integrating therapy: we coordinate EMDR/CBT during the acute phase to leverage neuroplasticity.

Esketamine vs. TMS: which is right for PTSD plus TRD?

Speed: esketamine may act in days; TMS generally builds over 2 to 6+ weeks.
Mechanism: esketamine is glutamatergic modulation; TMS is circuit-specific neuromodulation.
Session experience: esketamine requires monitored observation; TMS has none.
Driving: after esketamine, no driving until the next day; after TMS, driving is allowed.
Combination: for TRD plus PTSD, a sequenced or combined strategy (esketamine, TMS and EMDR/CBT) can optimize speed and durability.

Who is a good candidate?

We are a REMS-certified center. Common effects are transient (brief dissociation, dizziness, nausea, temporary blood pressure increases) and resolve during on-site observation. If you are in immediate crisis, call 988 (Suicide & Crisis Lifeline) or 911.

Adults with PTSD and treatment-resistant depression after best-practice trials (antidepressants plus trauma-focused therapy).
Active engagement (or readiness) for EMDR/CBT.
Medically appropriate for supervised intranasal therapy and follow-up.
Preference to consider a rapid-acting option while continuing evidence-based psychotherapy.

Esketamine in Wesley Chapel and Tampa

Florida TMS Clinic, Tampa: serving Tampa, South Tampa, Downtown, and Westshore. Same-week evaluations often available.

Florida TMS Clinic, Wesley Chapel: serving Wesley Chapel, New Tampa, Lutz, Land O' Lakes, and North Tampa communities.

Take the first step

If best-practice PTSD care hasn't been enough, our team can evaluate whether an esketamine trial makes sense, typically alongside EMDR/CBT and, when appropriate, TMS.